Maxon Introduces Cinebench 2024
Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists and creators of all types, is thrilled to announce the highly anticipated release of Cinebench 2024. This latest iteration of the industry-standard benchmarking software, which has been a cornerstone in computer performance evaluation for two decades, sets a new standard for performance evaluation, embracing cutting-edge technology to provide artists, designers, and creators with a more accurate and relevant representation of their hardware capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905630586/en/
Maxon Introduces Cinebench 2024: A New Standard for Performance Evaluation (Photo: Business Wire)
Redshift Rendering Engine Integration
Cinebench 2024 ushers in a new era by embracing the power of Redshift, Cinema 4D's default rendering engine. Unlike its predecessors, which utilized Cinema 4D's standard renderer, Cinebench 2024 utilizes the same render algorithms across both CPU and GPU implementations. This leap to the Redshift engine ensures that performance testing aligns seamlessly with the demands of modern creative workflows, delivering accurate and consistent results.
Dual Performance Evaluation: CPU and GPU
Cinebench 2024 reinstates GPU benchmarking, a feature absent from Cinebench for the past decade. The latest version not only evaluates CPU performance; it also provides insights into the GPU's capabilities, reflecting the evolving technological landscape of creative software and workflows.
Wider Platform Compatibility
Cinebench 2024 is designed to accommodate a broader range of hardware configurations. It seamlessly supports x86/64 architecture (Intel/AMD) on Windows and macOS, as well as Arm64 architecture to extend its reach to Apple silicon on macOS and Snapdragon® compute silicon on Windows, ensuring compatibility with the latest advancements in hardware technology. Redshift GPU performance can be evaluated on systems with compatible Nvidia, AMD and Apple graphics processors.
Unified Benchmarking Scene
Cinebench 2024 streamlines the benchmarking process by utilizing a consistent scene file for both CPU and GPU testing. This innovation enables users to discern the advantages of leveraging Redshift GPU, providing a real-world glimpse into the benefits of harnessing cutting-edge graphics hardware for rendering tasks.
Revamped User Interface
Cinebench 2024 introduces a revamped user interface that enhances the user experience and showcases the incredible artistic endeavors achieved with the Redshift render engine in Cinema 4D. This dynamic interface serves as a testament to the potential of the Redshift engine while offering users a more intuitive and visually engaging experience.
Under-the-Hood Enhancements
Beyond the surface, Cinebench 2024 brings forth a host of performance-enhancing features. With a threefold increase in memory footprint compared to Cinebench R23, the software caters to the memory-intensive demands of modern projects. Moreover, a six-fold rise in computational effort and utilization of newer instruction sets ensures a benchmark that resonates with the complexity and sophistication of contemporary creative projects.
Unparalleled Performance Evaluation
It's crucial to note that Cinebench 2024 scores cannot be directly compared to those of its predecessor, Cinebench R23. With the incorporation of Redshift, a different rendering engine, larger memory footprint, and more complex scenes, Cinebench 2024 offers a distinctly enhanced and accurate evaluation of modern hardware capabilities.
Availability
Cinebench 2024 is immediately available for download starting today on the official Maxon website. Creatives, gamers and technology enthusiasts are invited to explore this groundbreaking benchmarking tool and experience firsthand the leap in performance evaluation that it offers.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is composed of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905630586/en/
Contact information
Press Contact
Chloe Larby
Grithaus Agency
(e) chloe@grithaus.agency
(p) +44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 18:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2 It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.3 By depleting cells that produce an abnormal protein called Gd-IgA1 implicated in the pathogenesis, mezagitamab targets early steps in the process lea
Oremus Corporate Services Expands into Europe with Launch in Finland7.11.2025 17:23:00 EET | Press release
Oremus Corporate Services Private Limited, a multinational Finance and Accounting Advisory firm having its offices in the USA, India and the UK, has announced the extension of its services to Finland, marking the company’s foray into the European market. With over two decades of expertise in accounting, payroll, tax compliance, and advisory services, Oremus has earned trust as a technology-driven finance partner serving clients across geographies. Oremus is an ISAE 3402, ISO 27001, GDPR & DPDP Compliant Company, adhering to International Quality and Security Standards. “Finland isn’t just a new market for us — it’s the gateway to meaningful, growth-driven partnerships across Europe”. said Lalit Ananth Chawla, CEO of Oremus. Having established a strong reputation for delivering reliable Accounting and Advisory solutions to scale-ups and growing businesses, we seek to collaborate with like-minded firms and investors to build a trusted growth ecosystem. Our vision is to offer technology-d
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 16:00:00 EET | Press release
Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, President of Experian Software Solutions at Experian. “Experian continues to listen to our clients and focus heavily on product development across
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 15:12:00 EET | Press release
MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of MultiSafepay. In her new role, Lim oversees the overall business strategy and operations of MultiSafepay, leading the company to serve a fast-growing client base of SMEs (small and medium-sized enterprises) in Europe, leveraging innovative solutions to drive their inclusive growth. She now also sits on its board of directors, following approval from the Dutch central bank, De Nederlandsche Bank (DNB). Founder Olaf Geurs, who has served as CEO since establishing MultiSafepay in 1999, will remain Chief Technology Officer (CTO). Geurs will continue to serve on the board of directors, where he and the other existing members will be joined by Lim. In his
Organon Announces Agreement to Divest its JADA ® System for Up to $465 Million to Laborie7.11.2025 14:30:00 EET | Press release
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transfer to Laborie as part of the agreement. “I am incredibly proud of the work the JADA team and Organon have done to help more than 136,000 new mothers in over 20 countries, positioning JADA as a recognized standard of care in postpartum hemorrhage (PPH) management,” said Organon Interim Chief Executive Officer (“CEO”) Joseph Morriss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom